Correccións

During my pharmaceutical studies (or As I progressed in my pharmacy studies?), I became more and more aware of the complexity of Health Policy surrounding pharmaceutical products, and how difficult it is to set a price on health.

The question of ethics and equal access to care also arises, intra-country based on income and inter-country based on the country’s investment in health and therefore its level of development (I dont know how to say my last sentence in english sorry).

Reports of supply shortages for major therapeutic interest drugs in France and internationally have reached new heights in recent months.

While we have good reasons to hope that the worst of the covid-19 pandemic is now behind us, events such as the war in Ukraine and the energetic crisis lead to global economic turbulence and continue to demonstrate the vulnerability of health systems.

Inflation lead to higher costs for energy, raw materials and transport.

Combined with budgetary constraints and strictly (or highly?) controlled price in several countries, makes it difficult for manufacturers.

Especially of generic drugs, making some medicines at a loss or favoring countries where the price is higher.

Indeed, in addition to this, there is the climate constraint, given that the health sector will also have to do its own part to move towards a more sustainable (or responsible?) world.

Through the X Master’s at the X, I wish to get the academic knowledge that I need for the future to improve access to health care for all.

My aim is to ensure that patients can have access to their treatments, quickly, in a continue way, and at the optimal price.

I want to learn how health systems can be designed and implemented to work towards accessible and equitable health care, making an impact in the lives of patients all around the globe.